Events on 26 September 2023

Quality control in serology laboratory presentation

04/06/2019
Quality control in serology laboratory presentation, given at the IBMS London Branch Virology Discussion Group on 4th June 2019

Point of Care Testing Biopod Vol 1

04/11/2019
The IBMS Biopod is a monthly podcast for members. Each episode will feature experts from the field discussing their research and talking about the latest developments.

Phadia Academy Online Learning Platform

01/12/2022
Phadia Academy is an online learning platform by Thermo Fisher Scientific aimed at Lab staff primarily BMSes in Immunology Labs. It includes courses for autoimmune diseases, allergy, and our instruments. We would like to have it as a link on the IBMS webpage, as it was in previous years.

EUROIMMUN Symposium: Advancing Laboratory Excellence

19/07/2023
Allocated as Lecture/Study: 2h 15m
Allocated as Practical Element: 1h 00m
Allocated as Q&A/Discussion: 1h 15m

IBMS Congress 2023

25/09/2023
IBMS Congress 2023 is an important forum for progressing your professional skills and knowledge, supporting career development and promoting the profession.

Intensive Microtomy Training Course

25/09/2023
Full Hands-on Practical Microtomy Training course.

Microtomy is a skill that requires training and practice. The course is practical and hands-on for anyone who desire to work in histopathology department.

25-27th September 2023
2- 4th October 2023
9-11th October 2023
18-20th October 2023


CONGRESS 2023 - Spatial Transcriptomics: A novel tool to elucidate cell populations in non-melanoma skin cancers

26/09/2023
Non-melanoma skin cancers (NMSC) are on the rise, with around 156,000 cases diagnosed annually in the United Kingdom. Basal cell carcinoma (BCC) is the most predominant form that is encountered, and cutaneous squamous cell carcinoma (cSCC) accounts for 20% of all non-melanoma skin cancers. Although the vast majority of non-melanoma skin cancers have a good prognosis and can be cured by surgical intervention, they can cause the destruction of local tissue architecture due to tumour growth. Moreover, a small subset of tumours have poorer outcomes with metastases and mortality.

The underlying biological mechanisms governing a higher risk of recurrence, metastasis, and death remain poorly understood due to a lack of accurate risk stratification. Risk prediction is important in the management of NMSC, as it informs which patients require imaging, how frequently imaging should be performed and how frequently patients should be reviewed. It also informs which patients will benefit from wider surgical resection, adjuvant radiotherapy or sentinel lymph node biopsy. In the future, there is a role for the use of adjuvant immunotherapy for patients with particularly high-risk tumours. This presentation aims to highlight the use of single-cell and spatial transcriptomics analysis approaches in comprehensively mapping the localisation of the different cellular subpopulations in non-melanoma skin cancers. The ultimate aim is to develop better diagnostic tools and markers to predict patient risk status, which will lead to better clinical outcomes.

CONGRESS 2023 - Introduction of Digital Image Analysis into EQA Assessments

26/09/2023
Digital imaging for remote viewing to enable reporting is becoming increasingly prevalent in the NHS cellular pathology services. Sea change levels of improvement in the technology that enables digital image acquisition, viewing, transfer and storage has allowed its widespread deployment and adoption and concomitant to this has been the development of software applications to enable the analysis of those digital images for a huge variety of reasons.

In my talk I will discuss the application of digital image analysis to the scans of the slides that we assess as part of our routine external quality assessment (EQA) workload. Both as aids to improve the information and the accuracy of that information e.g., in the assessment of the proliferation marker Ki-67 in breast cancer to improve its use as a prognostic marker, and as a tool to verify and quality control our own processes and EQA materials e.g., the measurement of reproducibility and homogeneity in tissue and cell line samples used in the assessment of PD-L1 immunohistochemistry staining in non-small cell lung cancer.

CONGRESS 2023 - The Introduction of Digital Pathology EQA

26/09/2023
Delegates attending this session will learn about and gain knowledge on the introduction and application of the new EQA scheme to cover digital pathology in Cellular Pathology.

CONGRESS 2023 - The Reality of Digital Pathology Implementation

26/09/2023
This presentation will support the introduction of the Digital Pathology EQA explaining the assessment criteria and how the technical issues may be overcome in a routine laboratory.

Page 1 of 7

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7